Roth Capital raised the firm’s price target on PolyPid (PYPD) to $10 from $9 and keeps a Buy rating on the shares after meeting with its management following the company’s Q2 results. The firm expects a fairly uneventful pre-NDA meeting given solid D-PLEX100 clinical data, which Roth believes is poised to transform the treatment paradigm in SSI associated with colorectal cancer surgery, providing benefits to patients and healthcare systems, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYPD:
- PolyPid Reports Strong Phase 3 Results and Financial Update
- PolyPid Releases Mid-2025 Financial Update
- PolyPid’s Promising Outlook: Buy Rating Affirmed Amidst Positive Phase 3 Results and Strategic Advancements
- PolyPid Reports Positive Phase 3 Results and Strengthens Leadership
- PolyPid reports Q2 EPS (78c), consensus (55c)